Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APL-1202 plus epirubicin in recurrent intermediate/high-risk NMIBC
CTR20170169Phase 2Completed
- Sponsor
- Asieris Pharmaceuticals
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of APL-1202 + APL-1501 in bladder cancer, sponsored by Asieris Pharmaceuticals. Started Mar 2017; status: completed.
02
Drugs
APL-1202 + APL-1501
03
Conditions
bladder cancer
Beyond the preview
Go deeper on CTR20170169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170169.